Global /United States /Healthcare /Biotechnology /DCOY

Decoy Therapeutics Inc.

DCOY

• NASDAQ: DCOY • Delayed

5.54USD 1.2%

As of 13 June 2026, Decoy Therapeutics Inc. has a market cap of $2.95M USD, ranking #46211 globally and #5865 in the United States. It ranks #4094 in the Healthcare sector, and #803 in the Biotechnology industry.

Global Rank

46211

Country Rank

5865

Sector Rank

4094

Industry Rank

803

Key Stats

Market Cap

$2.95MUSD

Enterprise Value

-$7.76MUSD

EBITDA (TTM)

-$4.09MUSD

Net Income (TTM)

-$12.52MUSD

PB Ratio

0.5

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Frederick Pierce open_in_new

Employees

Website

decoytx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.2%	-5.8%	-13%	-47%	-88%	-29%	-96%	-100%	-100%

News

DCOY Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	DCOY ISIN: US79400X6022 Shares Out.: Shares Outstanding: 531.968K¹ Shares Float: 513.246K² TV: TradingView: NASDAQ: DCOY SA: Stock Analysis: NASDAQ: DCOY YF: Yahoo Finance: DCOY GF: Google Finance: NASDAQ: DCOY NQ: NASDAQ: DCOY BA: Barron's: DCOY MS: Morningstar: XNAS: DCOY	5.54 USD	TV: TradingView: NASDAQ: DCOY SA: Stock Analysis: NASDAQ: DCOY YF: Yahoo Finance: DCOY GF: Google Finance: NASDAQ: DCOY NQ: NASDAQ: DCOY BA: Barron's: DCOY MS: Morningstar: XNAS: DCOY

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Decoy Therapeutics Inc.

Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Cambridge, Massachusetts.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 6M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 5M%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 936K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 892K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 849K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 615K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 2M%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 2M%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 1M%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 1M%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 954K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 871K%	-	Germany

chevron_leftBack